Endothelial / cardiovascular
Endothelial dysfunction and vascular aging.
Decision support, not prescription. You decide.
Candidate agents
6 agents · tap to expand▶Empagliflozin (Jardiance)LeadStrongAn SGLT2 inhibitor with guideline-level cardiovascular outcome benefit; for the endothelial/vascular-aging lever this is the most solid agent on this list and should be taken seriously as disease-modifying therapy, not a peptide experiment.expand
An SGLT2 inhibitor with guideline-level cardiovascular outcome benefit; for the endothelial/vascular-aging lever this is the most solid agent on this list and should be taken seriously as disease-modifying therapy, not a peptide experiment.
▸Full clinical story
Beyond glucose lowering, empagliflozin reduces myocardial inflammation and oxidative stress and restores the NO-sGC-cGMP-PKG signaling axis, improving endothelial vasorelaxation and reducing cardiomyocyte stiffness; in human HFpEF myocardium it lowered ICAM-1, VCAM-1, TNF-alpha and IL-6 and reduced oxidative eNOS-dependent PKGIalpha oxidation/polymerization.
Strong. Mechanism is demonstrated in human HFpEF myocardium and murine models (ex-vivo/translational), and hard cardiovascular outcomes come from a large RCT: EMPA-REG OUTCOME (7,020 patients treated, primary MACE HR 0.86, 95.02% CI 0.74-0.99; CV death 38% and heart-failure hospitalization 35% relative risk reductions). The direct endothelial data are mechanistic, but the outcome data are RCT-grade, so the overall grade holds at strong.
Anecdotal community signal only for the vascular-aging/longevity use: some off-label and biohacker users take low-dose SGLT2 inhibitors hoping for endothelial and metabolic 'anti-aging' effects and report improved energy and weight. These are unverified self-reports, not how the outcome evidence was generated, and should be labeled as unproven extrapolation.
Context, not a protocol: approved cardiovascular/heart-failure dosing is 10 mg once daily orally (EMPA-REG used 10 or 25 mg). No validated 'endothelial' microdose exists.
Condition-specific flags: volume depletion and hypotension risk when combined with diuretics or other antihypertensives common in vascular patients; euglycemic DKA (hold during acute illness/surgery/fasting); genital mycotic and urinary infections (increased genital infection was the main adverse signal in EMPA-REG); caution with declining eGFR. Additive glucosuria/volume effects matter in the polypharmacy typical of CVD patients.
The best-supported agent here for cardiovascular risk with a genuine endothelial mechanism; a clinician can prescribe it on-label with outcome evidence, while recognizing the specific 'reverses endothelial aging' framing outruns what the trials measured.
▶SemaglutideStrongA GLP-1 receptor agonist with a positive dedicated cardiovascular outcome RCT in non-diabetic patients; for cardiovascular risk reduction this is high-quality, take-it-seriously evidence, though the 'endothelial' framing is inferred rather than the trial endpoint.expand
A GLP-1 receptor agonist with a positive dedicated cardiovascular outcome RCT in non-diabetic patients; for cardiovascular risk reduction this is high-quality, take-it-seriously evidence, though the 'endothelial' framing is inferred rather than the trial endpoint.
▸Full clinical story
Proposed vascular benefit is multifactorial: weight loss, blood-pressure and lipid improvement, reduced systemic inflammation, and possible direct effects on endothelial function and atherosclerotic plaque; the causal chain to endothelium specifically is mechanistically plausible but not what SELECT measured.
Strong for the outcome, at the level of MACE rather than a direct endothelial readout. In the SELECT RCT (17,604 patients with established CVD and overweight/obesity, no diabetes), weekly subcutaneous semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo (HR 0.80, 95% CI 0.72-0.90, P<0.001). This is a large, double-blind, placebo-controlled trial, so the therapeutic grade is strong; endothelial-specific benefit remains an inference.
Anecdotal community signal: widespread off-label use for weight loss and 'metabolic/cardiovascular longevity,' often at titrated or lower-than-label doses and sometimes via compounded product; users report weight and energy changes. These are unverified self-reports. Cardiovascular benefit in the trial required the full 2.4 mg dose and years of exposure, so lower-dose community use should not be presented as delivering the SELECT outcome.
Context, not a protocol: SELECT used subcutaneous 2.4 mg once weekly after standard dose escalation from 0.25 mg over ~16 weeks to limit GI effects.
Condition-specific flags: contraindicated with personal/family history of medullary thyroid carcinoma or MEN2; pancreatitis risk; adverse events (predominantly GI intolerance) led to more permanent discontinuations than placebo (16.6% vs 8.2%); delayed gastric emptying is relevant around anesthesia/procedures common in CVD patients; watch for hypoglycemia when stacked with insulin/sulfonylureas.
A genuinely evidence-based way to lower cardiovascular events in overweight patients with established CVD; solid to recommend for risk reduction, with honesty that 'improves the endothelium' is a mechanistic story layered on a MACE-endpoint trial.
▶ElamipretidePreclinicalA mitochondria-targeted (cardiolipin-binding) peptide with consistent but animal-only evidence for preserving coronary and renal microvascular endothelium; genuinely interesting mechanistically, but preclinical for this lever.expand
A mitochondria-targeted (cardiolipin-binding) peptide with consistent but animal-only evidence for preserving coronary and renal microvascular endothelium; genuinely interesting mechanistically, but preclinical for this lever.
▸Full clinical story
Elamipretide binds cardiolipin on the inner mitochondrial membrane, stabilizing cristae and improving mitochondrial bioenergetics; in vascular endothelial cells this preserved mitochondrial density, reduced oxidative stress and apoptosis, restored eNOS, and improved endothelium-dependent relaxation and microvascular density.
Preclinical. Evidence is from porcine metabolic-syndrome models: 4 weeks of subcutaneous elamipretide (0.1 mg/kg once daily) preserved coronary endothelial-cell mitochondria, restored eNOS and endothelium-dependent relaxation, and reduced subendocardial microvascular loss, with parallel findings protecting the renal microvasculature. These are controlled animal studies (n=6/group), not human trials, and myocardial perfusion itself was unchanged; human cardiovascular endothelial outcome data are lacking, so preclinical is correct. (Note: separate human trials of elamipretide in primary mitochondrial myopathy and HFrEF have been largely negative on their clinical endpoints.)
Anecdotal community signal: elamipretide/SS-31 appears in longevity and mitochondrial-optimization circles via research-chemical channels, dosed by self-experimenters for 'mitochondrial'/energy and vascular-aging goals; reports are subjective and sparse. This should be treated as unverified community use of an investigational peptide, not evidence of benefit.
Context, not a protocol: preclinical work used 0.1 mg/kg subcutaneously once daily; human trials have used fixed subcutaneous doses (e.g., ~40 mg/day). No validated human vascular-aging dose exists.
Condition-specific flags: investigational, not approved; injection-site reactions reported in trials; unknown interactions and no safety data for chronic off-label vascular use. Community sourcing carries purity/sterility risk.
A mechanistically elegant mitoprotective peptide with reproducible animal vascular benefit but no positive human cardiovascular endpoint yet; reasonable to watch, not to present to patients as an established endothelial therapy.
▶HumaninPreclinicalA mitochondria-derived cytoprotective peptide with in-vitro evidence against glucose-driven endothelial dysfunction; mechanistically appealing but preclinical, with no human vascular outcome data.expand
A mitochondria-derived cytoprotective peptide with in-vitro evidence against glucose-driven endothelial dysfunction; mechanistically appealing but preclinical, with no human vascular outcome data.
▸Full clinical story
In endothelial cells, humanin induces KLF2 (a master transcriptional regulator of endothelial quiescence) via ERK5, restoring eNOS, lowering endothelin-1, and reducing VCAM-1/E-selectin expression and monocyte adhesion, key steps in early atherogenic endothelial activation.
Preclinical (in vitro). The direct data are from human umbilical vein endothelial cells under high-glucose conditions, where humanin prevented monocyte (THP-1) adhesion and restored eNOS in a KLF2-dependent manner (effects abolished by KLF2 knockdown); a review situates humanin among mitochondrial-derived peptides for vascular aging. There are no animal outcome or human studies for the vascular endpoint, so preclinical is correct and direct human outcome evidence is explicitly lacking.
Anecdotal community signal: humanin and humanin analogs circulate in longevity/peptide communities as injectable 'mitochondrial'/anti-aging agents, but real-world use is far smaller than for MOTS-c or BPC-157, and vascular-specific self-report is minimal. Treat any such use as unverified anecdote with no efficacy established.
Context, not a protocol: no established human dose for any indication; community/research figures are inconsistent and derive from in-vitro or animal work rather than validated human protocols.
Condition-specific flags: unapproved investigational peptide; no human safety, interaction, or contraindication data in a cardiovascular population; community-sourced peptide carries purity/sterility risk. Endothelial findings are cell-culture only and should not be extrapolated to patients.
A biologically interesting endothelial-protective peptide at the earliest (in-vitro) stage; suitable as a research lead, not something to offer patients for cardiovascular or vascular-aging benefit.
▶MOTS-cPreclinicalA mitochondria-derived peptide proposed as both a therapeutic and a biomarker for vascular aging; a hypothesis-stage candidate for this lever, supported by mechanism and review-level discussion rather than direct vascular trials.expand
A mitochondria-derived peptide proposed as both a therapeutic and a biomarker for vascular aging; a hypothesis-stage candidate for this lever, supported by mechanism and review-level discussion rather than direct vascular trials.
▸Full clinical story
MOTS-c modulates AMPK, mTOR and sirtuin signaling in endothelial and vascular smooth-muscle cells, pathways that govern cellular metabolism, stress resilience, oxidative-stress handling and inflammation, and is proposed to counter mitochondrial dysfunction underlying endothelial aging.
Preclinical, and largely conceptual for the vascular endpoint. The only mapped source is a narrative review of mitochondrial-derived peptides in vascular aging; it frames MOTS-c's endothelial role mechanistically and as a biomarker candidate rather than reporting a controlled vascular outcome study. Direct human cardiovascular endothelial evidence for MOTS-c is absent, so preclinical is the honest ceiling and the vascular claim rests on pathway biology plus non-vascular MOTS-c literature.
Anecdotal community signal: MOTS-c is sold as a research/longevity peptide and injected by self-experimenters for metabolic, exercise-performance and 'anti-aging' goals; users report subjective energy and body-composition effects. There is no controlled vascular data behind these unverified reports, and they must be labeled as anecdote, not evidence.
Context, not a protocol: community regimens typically cite subcutaneous ~5-10 mg per week in divided doses or short cycles; these figures are unvalidated and derive from vendor/forum sources, not trials.
Condition-specific flags: unapproved investigational peptide with no human vascular safety data; unknown drug interactions (theoretical additive effects on metabolic/AMPK-active drugs like metformin); community-sourced material carries purity and sterility risk.
An intriguing mitochondrial-derived peptide with a coherent endothelial rationale but no direct human vascular evidence; appropriate as a research and biomarker interest, not as a therapy a clinician can stand behind for cardiovascular risk.
▶TadalafilEmergingA long-acting PDE5 inhibitor with small human signals of improved endothelial function and arterial stiffness; a reasonable, physiologically grounded 'emerging' option, not an outcome-proven cardiovascular therapy.expand
A long-acting PDE5 inhibitor with small human signals of improved endothelial function and arterial stiffness; a reasonable, physiologically grounded 'emerging' option, not an outcome-proven cardiovascular therapy.
▸Full clinical story
By inhibiting PDE5, tadalafil raises cGMP downstream of the NO pathway, promoting vasodilation and potentially improving endothelium-dependent relaxation and reducing arterial stiffness; this is the same NO-cGMP axis implicated in vascular aging.
Emerging. The direct human data are small and uncontrolled: in 20 men with BPH in whom an alpha-blocker was ineffective, daily tadalafil 5 mg improved reactive hyperemia index (1.36 to 1.89) and reduced brachial-ankle pulse-wave velocity (1701 to 1525 cm/s) over 4-12 weeks (before/after design, no placebo arm, n=20). A pharmacology review summarizes broader preclinical and trial-level interest in PDE5 inhibitors for cardiovascular, metabolic and aging indications. No large RCT shows PDE5 inhibition reduces cardiovascular events, so emerging is the honest grade.
Anecdotal community signal: daily low-dose tadalafil is popular off-label in longevity and men's-health circles for presumed endothelial, 'pump'/blood-flow and exercise benefits, often continuous 2.5-5 mg daily; users report subjective vascular and erectile improvements. This is unverified real-world enthusiasm, not proof of cardiovascular risk reduction.
Context, not a protocol: the endothelial study used 5 mg once daily; the general daily continuous dose seen is 2.5-5 mg.
Condition-specific flags: absolutely contraindicated with any nitrate and with soluble guanylate cyclase stimulators (e.g., riociguat) due to severe hypotension; caution with alpha-blockers and other antihypertensives; relevant because these co-medications are common in the vascular/BPH population this signal comes from.
Plausible mechanism and encouraging small human surrogate-marker data make it a defensible experimental adjunct for endothelial function, but a clinician should treat cardiovascular benefit as unproven and mind the nitrate/riociguat contraindications.
Matching protocol templates
Browse all →Fat loss, cellular energy enhancement, metabolic reset
Post-viral recovery, metabolic reset, endurance support
Fatigue management, metabolic flexibility, recomposition
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.